On Friday, Shares of Resolute Energy Corp (NYSE:REN), added 8.54% and closed at $26.06 in the last trading session. The last trading range of the stock ranges between $26.04 and $26.50. Resolute Energy Corporation, an independent oil and gas company, engages in the acquisition, exploitation, exploration for, and development of oil and gas properties in the United States. The company holds interests in the Aneth Field covering about 43,000 gross acres located in the Paradox Basin in southeast Utah; and covering 27,750 gross acres in the Permian Basin in west Texas and southeast New Mexico. As of December 31, 2015, its estimated net proved reserves were about 33.1 million barrels of oil equivalent.
Cempra Inc (NASDAQ:CEMP), jumped 1.34% and closed at $24.20 in the last trading session. The last trading range of the stock ranges between $23.77 and $25.00. The company’s Market capitalization is $1.28 Billion with the total Outstanding Shares of 51.99 million. Cempra, Inc. (CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, recently declared interim results showing anti-NASH effects in the first six nonalcoholic steatohepatitis (NASH) patients dosed with solithromycin in a Phase 2 study.
Contrast with baseline values, after 90 days of solithromycin treatment, all six NASH patients had a reduction in their nonalcoholic fatty liver disease (NAFLD) activity score (NAS) (mean reduction, 1.3) and their alanine aminotransferase (ALT) (mean reduction, 17.8 U/L). Five of six patients had a reduction in their aspartate aminotransferase (AST), and the sixth patient had an AST that was unchanged and normal (mean reduction for the six patients, 10.1 U/L).
There were also mean reductions in ballooning hepatocyte degeneration and inflammation, both of which are histological signs of NASH.
Solithromycin has been well tolerated in this study.
According to the National Institutes of Health, up to 16 million Americans, or two to five percent of the U.S. population, has NASH.
“We have been focusing on new treatments for NASH for the past 15 years and the early results we have seen with solithromycin are very promising for a patient population that urgently needs a new treatment option,” said Pierre Gholam, M.D., from Case Western Reserve University School of Medicine and principal investigator of the study.
“While this is a small number of patients and further work is required to confirm these data on a wider scale, the observation that solithromycin was able to lower NAS by an average of 1.3 points in just 13 weeks with a good safety profile does allow a good measure of optimism,” Gholam added.
TerraForm Power Inc (NASDAQ:TERP), jumped 0.36% and closed at $13.91 in the last trading session. The last trading range of the stock ranges between $13.03 and $14.55. During the 52-week trading session the minimum price at which share price traded, registered at $6.73 and reached to max level of $20.12. TerraForm Power, Inc. (TERP) (the “Company”), an owner and operator of clean energy power plants, recently declared that it has reached a settlement agreement with Appaloosa Investment Limited Partnership I (“Appaloosa”) to resolve its stockholder derivative suit, in addition to derivative claims by stockholders regardingthe Vivint Solar transaction, filed with the Court of Chancery of the State of Delaware (the “Court”). The settlement is subject to approval by the Court.
Under the terms of the agreement, the Company has agreed to improve its information technology infrastructure and make certain changes related to corporate governance. In connection with these programs, TerraForm Power will:
Segregate its information technology systems for key functions from SunEdison;
Grant Thomas Studebaker, or any successor in the role of the Company’s Chief Operating Officer, responsibility for TerraForm Power’s ordinary course commercial operations, subject to the authority of Peter Blackmore, TerraForm Power’s Interim CEO; this commitment will expire at the earlier of two years or when SunEdison sells its controlling stake in the Company; and
Seek to identify and appoint an additional independent director to the TerraForm Power Board.